Clinical Trial Update: A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating three different doses of inhaled AZD2115 in patients with chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD2115 (AZD2115)

Snippet

Sponsor: AstraZeneca | Conditions: COPD | Phase 2 | Status: COMPLETED